

Product Information
Name:DCC-2618
Brand:Biosynth
Description:DCC-2618 is a zirconium oxide-based compound that binds to the ATP binding site of the Bcr-Abl kinase domain. The compound inhibits the phosphorylation of tyrosine residues in proteins on which it has been targeted, leading to cell death. DCC-2618 is an orally bioavailable drug that is well tolerated by patients. It is a potent inhibitor of myeloproliferative disorders and cancer cells with constitutive activation of the Bcr-Abl kinase domain. Inhibition of this kinase leads to cell cycle arrest, apoptosis, and suppression of tumor growth in mice.
Notice:Our products are intended for lab use only. For any other use, please contact us.
Chemical properties
Molecular weight:489.47 g/mol
Formula:C26H21F2N5O3
Purity:Min. 95%